6703-00-0

Usage

Uses

Used in Veterinary Medicine:
2,4-dimethoxybutyrophenone is used as a sedative and anesthetic for the management of animals, providing calmness and reducing stress during medical procedures.
Used in Human Tranquilization:
In humans, 2,4-dimethoxybutyrophenone serves as a tranquilizer, helping to alleviate anxiety and promote relaxation.
Used in Addiction Treatment:
2,4-dimethoxybutyrophenone is being investigated for its potential use in treating addiction, leveraging its ability to modulate dopamine receptors and potentially reduce cravings.
Used in Schizophrenia Management:
2-4-dimethoxybutyrophenone is also being explored for its potential role in managing schizophrenia, due to its impact on dopamine pathways that are implicated in the disorder.
Used in Medicinal Chemistry and Drug Discovery:
2,4-dimethoxybutyrophenone's anti-inflammatory and antioxidant properties make it a compound of interest for further research and development in the field of medicinal chemistry and drug discovery.

Upstream product

• 557-93-7 2-bromoprop-1-ene 
• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 106-31-0 butanoic acid anhydride 
• 151-10-0 1,3-Dimethoxybenzene 
• 109-74-0 propyl cyanide 
• 141-75-3 butyryl chloride 

Downstream Products

• 117705-67-6 1-(2,4-dimethoxyphenyl)-1-butanol 
• 117690-69-4 4-(4-cyanobutoxy)-5-butyl-2-hydroxyacetophenone 
• 117690-82-1 5-butyl-2,4-dimethoxyacetophenone 
• 81468-73-7 1-(5-butyl-2,4-dihydroxyphenyl)ethan-1-one 
• 54459-33-5 2,4-dimethoxy-n-butylbenzene 

Relevant academic research and scientific papers

Conversion of Aldehydes to Branched or Linear Ketones via Regiodivergent Rhodium-Catalyzed Vinyl Bromide Reductive Coupling-Redox Isomerization Mediated by Formate

A regiodivergent catalytic method for direct conversion of aldehydes to branched or linear alkyl ketones is described. Rhodium complexes modified by PtBu2Me catalyze formate-mediated aldehyde-vinyl bromide reductive coupling-redox isomerization to form branched ketones. Use of the less strongly coordinating ligand, PPh3, promotes vinyl-to allylrhodium isomerization en route to linear ketones. This method bypasses the 3-step sequence often used to convert aldehydes to ketones involving the addition of pre-metalated reagents to Weinreb or morpholine amides.

Hf[N(SO2C8F17)2] 4-catalyzed Friedel-Crafts acylation in a fluorous biphase system

In a fluorous biphase system, Hf[N(SO2C8F 17)2]4 complex (1 mol %) catalyzes Friedel-Crafts acylation of aromatic compounds such as anisole, toluene and chlorobenzene, and the corresponding aromatic ketones are obtained in satisfactory to high yields. The catalyst is selectively soluble in lower fluorous phase and can be easily recovered by simple phase separation. Furthermore, the catalyst can be reused without decrease of activity in most cases.

Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease

This invention provides methods for the treatment or prevention of Alzheimer's disease which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene antagonist.

SUBSTITUTED PHENYL PHENOL LEUKOTRIENE ANTAGONISTS

Antagonists having a substituted phenyl phenol or a substituted phenolic biphenyl structure, and various derivatives thereof, are specific leukotriene antagonists. Their structures, use and synthesis are disclosed. Also, pharmaceutical formulations are disclosed for use in applications treating diseases or conditions characterized by excessive release of leukotriene B 4, one of the metabolites of arachidonic acid.The primary LTB 4 antagonistic structures are represented as: STR1

Leukotriene B4 Receptor Antagonists: The LY255283 Series of Hydroxyacetophenones

A series of hydroxyacetophenones was prepared for evaluation as leukotriene B4 (LTB4) receptor antagonists, culminating in 1-oxy>phenyl>ethanone (compound 35, LY255283).Using an assay for inhibition of specific LTB4 binding to human PMN, we found that substitution of a nonpolar substituent in the 5-position was required for activity.Best activity was realized with hydrogen in the 3-position, hydroxyl in the 2-position, short chain alkyl ketone in the 1-position, and a six- or eight-carbon chain linking the oxygen in the 4-position with an unsaturated terminal function.Compound 35, having an IC50 of 87 nM in the binding assay, was chosen for further preclinical evaluation.

ANTI-INFLAMMATORY AGENTS

This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.

The Chemistry of Nitrilium Salts. Part 1. Acylation of Phenols and Phenol Ethers with Nitriles and Trifluoromethanesulphonic Acid

Aliphatic nitriles, RCN (R = Me, n-Pr, CH2Cl, and CCl3), in the presence of trifluoromethanesulphonic acid have been found to react with a number of mono-, di-, and tri-substituted phenols and phenol ethers at room temperature to give ketones after hydrolysis of the reaction mixture.Moderate to good yields of acylation products are obtained in the majority of these reactions.The yield with malononitrile and succinonitrile, which are only slightly soluble in the reaction medium, are generally poor, and reaction involves only one of the available nitrile groups.Attempts to use diethyl ether and dichloromethane as solvents for some of these reactions were unsuccessful, but limited success was achieved with nitromethane.